Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04699643
What this trial is testing

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
EverNov Medicines (Zhuhai Hengqin) Co., Ltd 80
Early research (Phase 1)Study completedNCT03326752
What this trial is testing

Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC

Who this might be right for
Advanced Non Small Cell Lung Cancer
Dynavax Technologies Corporation 26
Testing effectiveness (Phase 2)UnknownNCT03946943
What this trial is testing

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Who this might be right for
Soft Tissue SarcomasUndifferentiated Pleomorphic Sarcoma
Di Wu 25
Testing effectiveness (Phase 2)Study completedNCT06076135
What this trial is testing

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRadiotherapyImmune Checkpoint Blockade+1 more
Chuangzhen Chen 24
Testing effectiveness (Phase 2)Study completedNCT02500121
What this trial is testing

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

Who this might be right for
Urothelial CarcinomaBladder Cancer
Matthew Galsky 108
Early research (Phase 1)UnknownNCT05222009
What this trial is testing

G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Granulocyte Colony-Stimulating FactorPD-1 Inhibitor
Sun Yat-sen University 25
Not applicableLooking for participantsNCT04892849
What this trial is testing

Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy

Who this might be right for
HNSCCNSCLCEsophageal Cancer+4 more
University of Erlangen-Nürnberg Medical School 200
Large-scale testing (Phase 3)Not Yet RecruitingNCT06957938
What this trial is testing

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Who this might be right for
Laryngeal CarcinomaHypopharyngeal Carcinoma
Fudan University 168
Testing effectiveness (Phase 2)UnknownNCT03311789
What this trial is testing

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Who this might be right for
Biliary Tract Cancer
Chinese PLA General Hospital 30
Not applicableUnknownNCT05162898
What this trial is testing

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

Who this might be right for
Recurrent Hepatocellular Cancer
Henan Cancer Hospital 90
Not applicableActive Not RecruitingNCT06865521
What this trial is testing

Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

Who this might be right for
Colo-rectal CancerPD-1 InhibitorAkkermansia Muciniphila
West China Hospital 22
Early research (Phase 1)Study completedNCT02903914
What this trial is testing

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Who this might be right for
Metastatic CancerSolid TumorsColorectal Cancer (CRC)+7 more
Incyte Corporation 260
Large-scale testing (Phase 3)UnknownNCT04789434
What this trial is testing

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Who this might be right for
Lymphoma, Large B-Cell, DiffuseTransplantationChemotherapy
Ruijin Hospital 94
Large-scale testing (Phase 3)Not Yet RecruitingNCT07686796
What this trial is testing

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Who this might be right for
Local Advanced Rectal CancerPD-1 InhibitorPCSK9 Inhibitor+4 more
Guangdong Provincial People's Hospital 148
Testing effectiveness (Phase 2)Looking for participantsNCT07281924
What this trial is testing

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Who this might be right for
Metastatic MelanomaLiver Metastases
University of Wisconsin, Madison 15
Testing effectiveness (Phase 2)Looking for participantsNCT05838729
What this trial is testing

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Who this might be right for
Head Neck CancerIntratumoral Injection
Coordination Pharmaceuticals, Inc. 16
Large-scale testing (Phase 3)Active Not RecruitingNCT05732805
What this trial is testing

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Who this might be right for
MelanomaMelanoma (Skin)Melanoma Stage III+4 more
Biocad 270
Not applicableStudy completedNCT03492242
What this trial is testing

Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction

Who this might be right for
ArthritisCancerCardiac Disease+5 more
Groupe Hospitalier Pitie-Salpetriere 1,000
Not applicableStudy completedNCT04586894
What this trial is testing

Adverse Myocardial and Vascular Side Effects of Immune Checkpoint Inhibitors

Who this might be right for
CancerImmune DefectCardiovascular Abnormalities
Assistance Publique - Hôpitaux de Paris 50
Early research (Phase 1)Not Yet RecruitingNCT07348107
What this trial is testing

ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

Who this might be right for
Advanced Pancreatic Ductal Adenocarcinoma
Daniel Breadner 10
Next Page